The Phase II trial assessed the efficacy and safety of the tablets. Credit: Towfiqu barbhuiya on Unsplash.

MedinCell has reported positive data from the Phase II SAIVE clinical study of ivermectin in preventing Covid-19 infection in a contact-based population.

The double-blind, parallel-group, randomised, placebo-controlled, multicentre trial was designed for assessing the efficacy and safety of ivermectin tablets, which are taken orally for 28 days.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It was conducted between March and November last year in Bulgaria.

The trial was conducted in 399 adult participants who were not vaccinated and were exposed to the virus within five days of screening.

Findings showed that the participants treated with ivermectin had a 72% statistically significant reduction in Covid-19 infection, compared to the placebo group.

See Also:

During the study, ivermectin given for 28 days showed acceptable tolerability and safety without any safety signals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The final analysis of the SAIVE clinical trial is planned to be shared later in a peer-reviewed publication.

MedinCell CEO Christophe Douat said: “The SAIVE study provides encouraging data demonstrating efficacy and safety of ivermectin in prevention of Covid-19 infection in a postexposure situation. It supports the development of a long-acting injectable.

“Such a longacting injectable would provide a complementary tool against Covid-19. Several candidate formulations of ivermectin are ready for clinical batch manufacturing to start regulatory preclinical and clinical development.

“We will be reviewing the strategy for this asset based on this top line result and the upcoming comprehensive analysis of the study.”

The company stated that the trial was conducted to support the mdc-TTG programme.

The programme aims to prevent Covid-19 infection for weeks or months through a single injection of a long-acting formulation of ivermectin, which was developed using MedinCell’s BEPO technology.